$26.38
+0.51 (+1.97%)
BEAM News2 articles
CRISPR Therapeutics Surges 12% on Gene-Editing Sector Rally
CRISPR Therapeutics shares surged 12% in New York trading, buoyed by a sector-wide gene-editing rally and Eli Lilly's $1.9 billion deal with Ascidian Therapeutics.
Beam Global Surges on European Patent, but Q1 Woes Linger
BEEM surged 28% premarket on a new European patent for battery thermal management, but the company must convert its $9M backlog into Q2 revenue to offset a 51% Q1 revenue drop.